» Articles » PMID: 32664956

The Sputum Microbiome is Distinct Between COPD and Health, Independent of Smoking History

Abstract

Background: Airway bacterial dysbiosis is a feature of chronic obstructive pulmonary disease (COPD). However, there is limited comparative data of the lung microbiome between healthy smokers, non-smokers and COPD.

Methods: We compared the 16S rRNA gene-based sputum microbiome generated from pair-ended Illumina sequencing of 124 healthy subjects (28 smokers and 96 non-smokers with normal lung function), with single stable samples from 218 COPD subjects collected from three UK clinical centres as part of the COPDMAP consortium.

Results: In healthy subjects Firmicutes, Bacteroidetes and Actinobacteria were the major phyla constituting 88% of the total reads, and Streptococcus, Veillonella, Prevotella, Actinomyces and Rothia were the dominant genera. Haemophilus formed only 3% of the healthy microbiome. In contrast, Proteobacteria was the most dominant phylum accounting for 50% of the microbiome in COPD subjects, with Haemophilus and Moraxella at genus level contributing 25 and 3% respectively. There were no differences in the microbiome profile within healthy and COPD subgroups when stratified based on smoking history. Principal coordinate analysis on operational taxonomic units showed two distinct clusters, representative of healthy and COPD subjects (PERMANOVA, p = 0·001).

Conclusion: The healthy and COPD sputum microbiomes are distinct and independent of smoking history. Our results underline the important role for Gammaproteobacteria in COPD.

Citing Articles

Burn inhalation injury and intubation with dexamethasone-eluting endotracheal tubes modulate local microbiome and alter airway inflammation.

Gonzales G, Malka R, Bizios R, Dion G, Guda T Front Bioeng Biotechnol. 2025; 13:1524013.

PMID: 40078791 PMC: 11897493. DOI: 10.3389/fbioe.2025.1524013.


Keystone bacteria dynamics in chronic obstructive pulmonary disease (COPD): Towards differential diagnosis and probiotic candidates.

KavianFar A, Taherkhani H, Lanjanian H, Aminnezhad S, Ahmadi A, Azimzadeh S Heliyon. 2025; 11(4):e42719.

PMID: 40040961 PMC: 11876909. DOI: 10.1016/j.heliyon.2025.e42719.


NTHi killing activity is reduced in COPD patients and is associated with a differential microbiome.

Gopalakrishnan V, Sparklin B, Kim J, Bouquet J, Kehl M, Kenny T Respir Res. 2025; 26(1):45.

PMID: 39885466 PMC: 11781068. DOI: 10.1186/s12931-025-03113-z.


Oncogene-addicted solid tumors and microbiome-lung cancer as a main character: a narrative review.

Guardamagna M, Meyer M, Berciano-Guerrero M, Mesas-Ruiz A, Cobo-Dols M, Perez-Ruiz E Transl Lung Cancer Res. 2024; 13(8):2050-2066.

PMID: 39263011 PMC: 11384476. DOI: 10.21037/tlcr-24-216.


A metagenomic next-generation sequencing (mNGS)-based analysis of bronchoalveolar lavage samples in patients with an acute exacerbation of chronic obstructive pulmonary disease.

Wu J, Zhang Y, Duan J, Wei Y, Miao Y J Mol Histol. 2024; 55(5):709-719.

PMID: 39060894 DOI: 10.1007/s10735-024-10225-1.


References
1.
Charlson E, Chen J, Custers-Allen R, Bittinger K, Li H, Sinha R . Disordered microbial communities in the upper respiratory tract of cigarette smokers. PLoS One. 2010; 5(12):e15216. PMC: 3004851. DOI: 10.1371/journal.pone.0015216. View

2.
Erb-Downward J, Thompson D, Han M, Freeman C, McCloskey L, Schmidt L . Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One. 2011; 6(2):e16384. PMC: 3043049. DOI: 10.1371/journal.pone.0016384. View

3.
Shukla S, Walters E, Simpson J, Keely S, Wark P, OToole R . Hypoxia-inducible factor and bacterial infections in chronic obstructive pulmonary disease. Respirology. 2019; 25(1):53-63. DOI: 10.1111/resp.13722. View

4.
Morris A, Beck J, Schloss P, Campbell T, Crothers K, Curtis J . Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med. 2013; 187(10):1067-75. PMC: 3734620. DOI: 10.1164/rccm.201210-1913OC. View

5.
Dickson R, Martinez F, Huffnagle G . The role of the microbiome in exacerbations of chronic lung diseases. Lancet. 2014; 384(9944):691-702. PMC: 4166502. DOI: 10.1016/S0140-6736(14)61136-3. View